KR20030036686A - Vegf 억제 활성이 있는 퀴놀린 유도체 - Google Patents

Vegf 억제 활성이 있는 퀴놀린 유도체 Download PDF

Info

Publication number
KR20030036686A
KR20030036686A KR10-2003-7001934A KR20037001934A KR20030036686A KR 20030036686 A KR20030036686 A KR 20030036686A KR 20037001934 A KR20037001934 A KR 20037001934A KR 20030036686 A KR20030036686 A KR 20030036686A
Authority
KR
South Korea
Prior art keywords
alkyl
cyano
ethyl
quinoline
propoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR10-2003-7001934A
Other languages
English (en)
Korean (ko)
Inventor
헨네퀸라우렌트프란코이스안드레
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20030036686A publication Critical patent/KR20030036686A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2003-7001934A 2000-08-09 2001-08-08 Vegf 억제 활성이 있는 퀴놀린 유도체 Abandoned KR20030036686A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00402254.7 2000-08-09
EP00402254 2000-08-09
PCT/GB2001/003553 WO2002012226A1 (en) 2000-08-09 2001-08-08 Quinoline derivatives having vegf inhibiting activity

Publications (1)

Publication Number Publication Date
KR20030036686A true KR20030036686A (ko) 2003-05-09

Family

ID=8173805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7001934A Abandoned KR20030036686A (ko) 2000-08-09 2001-08-08 Vegf 억제 활성이 있는 퀴놀린 유도체

Country Status (14)

Country Link
US (2) US7371765B2 (cg-RX-API-DMAC7.html)
EP (1) EP1313726A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004505964A (cg-RX-API-DMAC7.html)
KR (1) KR20030036686A (cg-RX-API-DMAC7.html)
CN (1) CN1315822C (cg-RX-API-DMAC7.html)
AU (2) AU7653601A (cg-RX-API-DMAC7.html)
BR (1) BR0113056A (cg-RX-API-DMAC7.html)
CA (1) CA2415469A1 (cg-RX-API-DMAC7.html)
IL (2) IL153947A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000252A (cg-RX-API-DMAC7.html)
NO (1) NO326315B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523358A (cg-RX-API-DMAC7.html)
WO (1) WO2002012226A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300217B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
AU2008202205B2 (en) * 2003-12-23 2009-09-10 Pfizer Inc. Novel quinoline derivatives
AP2006003619A0 (en) * 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
KR20080027923A (ko) 2005-08-08 2008-03-28 화이자 인코포레이티드 Vegf-r 억제제의 염 및 다형체
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
CN101723894B (zh) * 2009-12-03 2011-12-28 南京大学 N-喹啉酰胺类衍生物及其制法与用途
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2016161952A1 (zh) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
CN114929225B (zh) * 2020-01-19 2024-06-28 正大天晴药业集团股份有限公司 用于治疗类风湿性关节炎的喹啉衍生物
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス,インク. フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CN120289432B (zh) * 2025-06-12 2025-09-05 上海健康医学院 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36256A (en) * 1862-08-19 Improvement in sewing-m ach ines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
AU719392B2 (en) 1996-10-01 2000-05-11 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CZ303899B6 (cs) * 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

Also Published As

Publication number Publication date
CN1446212A (zh) 2003-10-01
EP1313726A1 (en) 2003-05-28
BR0113056A (pt) 2003-07-08
AU7653601A (en) 2002-02-18
CA2415469A1 (en) 2002-02-14
AU2001276536B2 (en) 2007-01-04
NO326315B1 (no) 2008-11-10
US7371765B2 (en) 2008-05-13
MXPA03000252A (es) 2003-06-06
WO2002012226A1 (en) 2002-02-14
NO20030625D0 (no) 2003-02-07
US20030199491A1 (en) 2003-10-23
AU2001276536B9 (en) 2002-02-18
IL153947A0 (en) 2003-07-31
CN1315822C (zh) 2007-05-16
IL153947A (en) 2008-12-29
NZ523358A (en) 2004-09-24
NO20030625L (no) 2003-02-07
JP2004505964A (ja) 2004-02-26
ZA200300217B (en) 2004-04-08
US20080312273A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
KR100834823B1 (ko) 신놀린 화합물
US7371765B2 (en) Quinoline derivatives having VEGF inhibiting activity
KR100838617B1 (ko) 혈관형성 억제제로서의 퀴나졸린 유도체
KR100860295B1 (ko) 퀴나졸린 유도체
US7268230B2 (en) Quinazoline compounds
KR20030029812A (ko) 화학적 화합물
AU2001276536A1 (en) Quinoline derivatives having vegf inhibiting activity
AU2001276521A1 (en) Cinnoline compounds
WO2002016348A1 (en) Antiangiogenic bicyclic derivatives
AU2001279938A1 (en) Indole, azaindole and indazole derivatives having VEGF inhibiting activity
US20080058342A1 (en) Quinazoline Derivatives As Angiogenesis Inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060628

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070627

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080311

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070627

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080404

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080311

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090209

Appeal identifier: 2008101003033

Request date: 20080404

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080404

Decision date: 20090209

Appeal identifier: 2008101003033

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080404

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080404

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071127

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080701

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20090209

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080604

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee